RenovoRx, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNXT Nasdaq 2836 renovorx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RenovoRx, Inc.

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - Feb 26th, 2025 1:00 pm
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - Feb 13th, 2025 1:00 pm
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Feb 11th, 2025 12:00 pm
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement - Feb 7th, 2025 8:11 am
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Feb 7th, 2025 1:49 am
RenovoRx Announces Proposed Public Offering - Feb 6th, 2025 9:05 pm
ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer - Jan 27th, 2025 5:48 pm
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 - Jan 27th, 2025 1:00 pm
Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long - Jan 23rd, 2025 12:32 pm
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 - Jan 8th, 2025 1:00 pm
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform - Dec 30th, 2024 1:00 pm
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer - Dec 11th, 2024 1:00 pm
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET - Dec 10th, 2024 1:00 pm
RenovoRx begins commercialisation of RenovoCath device - Dec 6th, 2024 10:01 am
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System - Dec 5th, 2024 1:00 pm
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Nov 20th, 2024 1:45 pm
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights - Nov 14th, 2024 1:00 pm
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully - Sep 26th, 2024 11:29 am
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - Sep 25th, 2024 12:30 pm
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer - Sep 19th, 2024 12:30 pm